

## **YONDELIS® (trabectedin)**

### **Use of YONDELIS in Combination with Antiemetics**

#### **SUMMARY**

- YONDELIS is indicated for the treatment of patients with unresectable or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen.<sup>1</sup>
- Administer dexamethasone 20 mg intravenously (IV) 30 minutes prior to each dose of YONDELIS.<sup>1</sup>
- In the phase 3 registration study (SAR-3007) which evaluated the use of trabectedin vs dacarbazine in patients with advanced LPS or LMS<sup>2</sup>, premedication with dexamethasone (or an equivalent IV corticosteroid) was required for patients in the trabectedin group. Optional treatment with additional antiemetic drugs, such as 5-HT<sub>3</sub> receptor antagonists or additional corticosteroids, was permitted. The antiemetic aprepitant, a CYP3A4 inhibitor, was to be used with caution due to potential for drug interactions.<sup>3</sup>
  - Information regarding the specific types of antiemetics used during the study or the frequency of use is not available.
- In addition to dexamethasone, antiemetic therapy with 5-HT<sub>3</sub> receptor antagonists and/or metoclopramide has been reported during phase 2 studies of trabectedin in soft tissue sarcoma.<sup>4-9</sup>
- Please refer to the institutional and national guidelines regarding the use of antiemetics during treatment with YONDELIS.
- Please refer to the DOSAGE AND ADMINISTRATION and DRUG INTERACTIONS sections of the full Prescribing Information.

#### **LITERATURE SEARCH**

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 18 December 2024.

#### **REFERENCES**

1. YONDELIS (trabectedin) [Prescribing Information]. Horsham, PA: Janssen Products, LP; <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/YONDELIS-pi.pdf>.
2. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized, multicenter clinical trial. *J Clin Oncol*. 2016;34(8):786-793.
3. Data on File. Trabectedin Clinical Study Report. Janssen Research & Development, LLC. Protocol ET743-SAR-3007; page 34; 2014.
4. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. *J Clin Oncol*. 2004;22(8):1480-1490.
5. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. *J Clin Oncol*. 2004;22(5):890-899.
6. Paz-Ares L, López-Pousa A, Poveda A, et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. *Invest New Drug*. 2012;30(2):729-740.
7. Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. *Lancet Oncol*. 2015;16(4):406-416.

8. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. *J Clin Oncol.* 2004;23(3):576-584.

9. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. *J Clin Oncol.* 2005;23(24):5484-5492.